Study based on well-tolerated doses with no reported DLTs of COM701 identified in monotherapy dose escalation arm of Phase 1 study
PR Newswire
HOLON, Israel, May 20, 2019
PR Newswire
HOLON, Israel, May 20, 2019
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey